ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
Get Alerts ANIP Hot Sheet
Join SI Premium – FREE
BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows:
| Capital One 1st Annual Biotech/Biopharma Disruptors Event | |
| Date: | Tuesday, May 14, 2024 |
| Time: | 12:15pm ET |
| To schedule a 1x1 meeting with management, please contact [email protected] | |
| H.C. Wainwright 2nd Annual BioConnect Conference at NASDAQ | |
| Date: | Monday, May 20, 2024 |
| Time: | 9:00am ET |
| Webcast: | Click Here |
| To schedule a 1x1 meeting with management, please contact [email protected]. | |
The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin® Gel, strengthening its Generics business with enhanced research and development capabilities, leveraging its U.S. based manufacturing footprint, and delivering innovation in Established Brands. For more information, please visit our website www.anipharmaceuticals.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]
Source: ANI Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- HTX Research Examines U.S. AI Equities: Technology Remains Early, While Capital Expenditure and Valuations Have Entered the Late Cycle
- Memecoin Launches Today: How MemeToro Uses AI Agents to Build Fair Launch Ecosystems
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share